Antifungal prophylaxis during neutropenia and immunodeficiency
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Fungal infections represent a major source of morbidity and mortality in patients with almost all types of immunodeficiencies. These infections may be nosocomial (aspergillosis) or community acquired (cryptococcosis), or both (candidiasis). Endemic mycoses such as histoplasmosis, coccidioidomycosis, and penicilliosis may infect many immunocompromised hosts in some geographic areas and thereby create major public health problems. With the wide availability of oral azoles, antifungal prophylactic strategies have been extensively developed. However, only a few well-designed studies involving strict criteria have been performed, mostly in patients with hematological malignancies or AIDS. In these situations, the best dose and duration of administration of the antifungal drug often remain to be determined. In high-risk neutropenic or bone marrow transplant patients, fluconazole is effective for the prevention of superficial and/or systemic candidal infections but is not always able to prolong overall survival and potentially selects less susceptible or resistant Candida spp. Primary prophylaxis against aspergillosis remains investigative. At present, no standard general recommendation for primary antifungal prophylaxis can be proposed for AIDS patients or transplant recipients. However, for persistently immunocompromised patients who previously experienced a noncandidal systemic fungal infection, prolonged suppressive antifungal therapy is often indicated to prevent a relapse. Better strategies for controlling immune deficiencies should also help to avoid some potentially life-threatening deep mycoses. When prescribing antifungal prophylaxis, physicians should be aware of the potential emergence of resistant strains, drug-drug interactions, and the cost. Well-designed, randomized, multicenter clinical trials in high-risk immunocompromised hosts are urgently needed to better define how to prevent severe invasive mycoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213 · cited 1×
“In most areas of the world, this fungal infection occurs in 5 to 10% of HIV-infected patients (86, 262), but in Africa it affects up to 30% (217), and it may become an even larger problem in Thailand (147).”
BackgroundRex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 2×
“glabrata in BMT patients who were receiving fluconazole prophylaxis (380).”
BackgroundCandida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798 · cited 1×
“Hematogenous candidiasis also follows colonization of the mouth or gastrointestinal tract (42, 72, 297), as reported for patients hospitalized in surgical intensive care units (263).”
BackgroundEpidemiology of nosocomial fungal infections
Fridkin, S. K., & Jarvis, W. R. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.499 · Cited by 782
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
WHEAT, L. J., CONNOLLY-STRINGFIELD, P. A., BAKER, R. L., CURFMAN, M. F., EADS, M. E., ISRAEL, K. S., NORRIS, S. A., WEBB, D. H., & ZECKEL, M. L. (1990) · Medicine · doi:10.1097/00005792-199011000-00004 · Cited by 651
Weems, J. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.3.756 · Cited by 399 · cited 1×
“parapsilosis (187, 362) may also emerge as a significant pathogen, particularly in patients receiving parenteral nutrition.”
BackgroundRisk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369
Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318
Cited by
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Interventions for treating oral mucositis for patients with cancer receiving treatment
Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., & Meyer, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001973.pub4 · Cited by 674
Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., & Boeckh, M. (2000) · Blood · doi:10.1182/blood.v96.6.2055 · Cited by 511
Transcription Profiling of Candida albicans Cells Undergoing the Yeast-to-Hyphal Transition
Nantel, A., Dignard, D., Bachewich, C., Harcus, D., Marcil, A., Bouin, A.-P., Sensen, C. W., Hogues, H., van het Hoog, M., Gordon, P., et al. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-05-0272 · Cited by 378
“determined by the immune state of the host (Lortholary and Dupont, 1997; Ashman, 1998).”
BackgroundAntifungal Resistance in Pathogenic Fungi
Perea, S., & Patterson, T. F. (2002) · Clinical Infectious Diseases · doi:10.1086/344058 · Cited by 289
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A.-M., Littlewood, A., McCabe, M. G., Meyer, S., Khalid, T., & Riley, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000978.pub5 · Cited by 262
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 184
Self-citationKanayama, M., Inoue, M., Danzaki, K., Hammer, G., He, Y.-W., & Shinohara, M. L. (2015) · Nature Communications · doi:10.1038/ncomms6779 · Cited by 114
IL-1 Coordinates the Neutrophil Response to C. albicans in the Oral Mucosa
Altmeier, S., Toska, A., Sparber, F., Teijeira, A., Halin, C., & LeibundGut-Landmann, S. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005882 · Cited by 112
“The relevance of neutrophils in protection from oropharyngeal candidiasis is also evidenced by the high incidence of the disease in hemato-oncological patients with bone marrow aplasia [8,9].”
Background
Metadata
- Authors
- Lortholary, O., & Dupont, B.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1997-07
- Volume
- 10
- Issue
- 3
- Pages
- 477-504
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2117608450
- Cited by
- 112
- References
- 12
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.